Article
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2021
Gajjar Amar, Robinson Giles W, Smith Kyle S, Lin Tong, Merchant Thomas E, Chintagumpala Murali, Mahajan Anita, Su Jack, Bouffet Eric, Bartels Ute, Schechter Tal, Hassall Tim, Robertson Thomas, Nicholls Wayne, Gururangan Sridharan, Schroeder Kristin, Sullivan Michael, Wheeler Greg, Hansford Jordan R, Kellie Stewart J, McCowage Geoffrey, Cohn Richard, Fisher Michael J, Krasin Matthew J, Stewart Clinton F, Broniscer Alberto, Buchhalter Ivo, Tatevossian Ruth G, Orr Brent A, Neale Geoff, Klimo Paul, Boop Frederick, Srinivasan Ashok, Pfister Stefan M, Gilbertson Richard J, Onar-Thomas Arzu, Ellison David W, Northcott Paul A
Abstract excerpt
PURPOSE: SJMB03 (ClinicalTrials.gov identifier: NCT00085202) was a phase III risk-adapted trial that aimed to determine the frequency and clinical significance of biological variants and genetic alterations in medulloblastoma. PATIENTS AND METHODS: Patients 3-21 years old were stratified into average-risk and high-risk treatment groups based on metastatic status and extent of resection. Medulloblastomas were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.